Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Review Pathway Drug Review Europe

EU Accelerated Assessment Tracker

  • News

Executive Summary

Pharming’s leniolisib has lost its accelerated assessment status at the European Medicines Agency while Krystal Biotech’s beremagene geperpavec will be fast-tracked once a filing has been made.

You may also be interested in...



New EU Filings

Givinostat, Italfarmaco’s investigational treatment for Duchenne muscular dystrophy, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

New Pink Sheet PRIME Tracker Reveals The Companies With The Most Entries On EMA Scheme

Securing a place on the European Medicines Agency’s priority medicines scheme is not easy, but some companies have managed to make the grade more than once.

Products Targeting Alzheimer's, Duchenne & COVID-19 Among New EU Filings

EU marketing authorization applications have been submitted for a number of new drugs, including Eli Lilly’s donanemab, Italfarmaco's givinostat and Arcturus Therapeutics/CSL’s ARCT-154.

Table

View full table

Topics

Related Companies

Tags:
Review Pathway Drug Review Europe
Latest Headlines

BrainStorm’s NurOwn Gets Many, Many Thumbs Down From US FDA Panel

Imbruvica, Enbrel, Stelara Offer Best Chance Of Savings From Medicare Negotiation In First Round

FTC Commissioner Recusal Decisions Should Be Public, US Chamber Of Commerce Says

Preparing For A Shutdown: US FDA To Retain 81% Of Workforce, Thanks Mostly To User Fees

See All
UsernamePublicRestriction

Register

PS147727

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By